Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $28000.0.

  • Alaunos Therapeutics' Non Operating Income rose 2173.91% to $28000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $79000.0, marking a year-over-year decrease of 9632.04%. This contributed to the annual value of $133000.0 for FY2024, which is 8730.92% down from last year.
  • Alaunos Therapeutics' Non Operating Income amounted to $28000.0 in Q3 2025, which was up 2173.91% from $19000.0 recorded in Q2 2025.
  • Alaunos Therapeutics' 5-year Non Operating Income high stood at $2.0 million for Q4 2023, and its period low was -$791000.0 during Q2 2023.
  • For the 5-year period, Alaunos Therapeutics' Non Operating Income averaged around -$96555.6, with its median value being $16000.0 (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 215483.87% in 2022, then skyrocketed by 41771.16% in 2023.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' Non Operating Income stood at -$743000.0 in 2021, then increased by 14.13% to -$638000.0 in 2022, then skyrocketed by 417.71% to $2.0 million in 2023, then plummeted by 99.36% to $13000.0 in 2024, then surged by 115.38% to $28000.0 in 2025.
  • Its Non Operating Income was $28000.0 in Q3 2025, compared to $19000.0 in Q2 2025 and $19000.0 in Q1 2025.